Non-hodgkin's Lymphoma
Conditions
Keywords
NHL，19+22
Brief summary
To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.
Detailed description
SL19+22 injection is a CAR-T product independently developed by Senlang that targets both CD19 and CD22. Based on the traditional CAR T treatment regimen, the CAR structure was designed, and the activation mode of T cells was changed by using cytokine combination amplification and improved transfection technology. The Main research objectives: To evaluate the safety and efficacy of SL19+22 in patients with recurrent or refractory non-Hodgkin's lymphoma The Secondary research objectives: To investigate the cytokinetic characteristics of SL19+22 in patients with recurrent or refractory non-Hodgkin's lymphoma.
Interventions
BIOLOGICALCD19+22 CAR-T cells
Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
Sponsors
Hebei Senlang Biotechnology Inc., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Sign the informed consent form and be able to comply with the visit, treatment regimen, laboratory examination and other requirements of the study as stipulated in the trial flow chart; 2. The diagnosis of patients with relapsed or refractory non-hodgkin lymphoma; 3. The definition of recurrent or refractory non-Hodgkin lymphoma: Patients with DLBCL, pmbcl and TFL diagnosed by histopathology are resistant to standard treatment; Or PD after at least second-line standard treatment; Or the last treatment effect was SD and the duration was no longer than 6 months; Or CD20 positive patients were ineffective or relapsed after anti-CD20 monoclonal antibody treatment; Or PD after autologous hematopoietic stem cell transplantation or recurrence confirmed by biopsy within 12 months; Or patients undergoing salvage treatment after autologous hematopoietic stem cell transplantation had no remission or recurrence after end-line treatment; 4. There should be at least one measurable tumor foci according to the RECIST version 1.1; 5. ECOG Scores: 0\ 2; 6. The expression of CD19 and/or CD22 on the tumor cells are reported as positive by either immunohistochemistry or flow cytometry; 7. Estimated survival time is longer than 3 months; 8. Main organ functions shall meet the following requirements: serum creatinine ≤1.5 times the upper limit of normal value (ULN); ALT ULN 2.5 or less; AST ULN 2.5 or less; Total bilirubin ≤ 1.5ULN; Left ventricular ejection fraction (LVEF) ≥45%; Hemoglobin ≥90g/L; Platelet count ≥50×109/L; absolute Neutrophil count (ANC) ≥1.0×109/L; Blood oxygen saturation \>92%； 9. Peripheral blood mononuclear immune cells must be collected at least 2 weeks after the last radiotherapy or systemic treatment.
Exclusion criteria
1. Serious cardiac insufficiency； 2. Has a history of severe pulmonary function damaging; 3. Coexisting with severe or persistent infection that cannot be effectively controlled; 4. Patients with a history of other malignancies, except those with non-melanoma skin cancer or carcinoma in situ (eg, cervical cancer, bladder cancer, breast cancer) who have received curative treatment at least 2 years prior to screening without disease recurrence; 5. Presence of metabolic diseases (except diabetes and Dyslipidemia); 6. Presence of severe autoimmune diseases or immunodeficiency disease; 7. Patients with active hepatitis B or hepatitis C virus infection; 8. Patients with HIV infection or syphilis infection; 9. Has a history of serious allergies on Biological products (including antibiotics); 10. Participated in any other clinical drug trial for the last three months(except clinicaltrials of CART ); 11. Being pregnant, lactating, or planing on pregnancy in the next 12 months. 12. Any situations that the researchers believe will increase the risks for the subject or affect the results of the study(have a history of serious mental illness, drug abuse and addiction).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Incidence and severity of adverse events | First month post CAR-T cells infusion | To evaluate the possible adverse events could occurred within first month post infusion. |
| Efficacy: Overall Remission Rate (ORR) | 3 months post CAR-T cells infusion | Overall Remission Rate (ORR) including partial remission and complete remission rate after infusion of SL19+22 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy:duration of response (DOR) | 24 months post CAR-T cells infusion | duration of response (DOR) |
| Efficacy: progression-free survival (PFS) | 24 months post CAR-T cells infusion | progression-free survival (PFS) time |
| CAR-T proliferation | 3 months post CAR-T cells infusion | the copy number of CD19 and CD22 CAR- T cells in the genomes of PBMC by qPCR |
| Cytokine release | First month post CAR-T cells infusion | Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry |
Countries
China
Contacts
Primary ContactPeihua Lu, PhD&M
Backup ContactJianqiang Li, PhD&M
Outcome results
None listed